QURE Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
uniQure N.V. had $16.1M of revenue in fiscal 2025, down 40.6% on the year before. Over five years, revenue changed β15.6% a year on average.
Last close Β· Oct 23, 2026
$22.43
2.9%Hi! I read uniQure N.V.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β40.6%
No. Sales fell 40.6% last year.
Does it make a profit?
β1,236.0%
No. It lost money last year.
Does profit turn into cash?
β1,108.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· uniQure N.V. had $16.1M of revenue in fiscal 2025, down 40.6% on the year before. Over five years, revenue changed β15.6% a year on average. Its operating margin was β1,151.4%, down 471.8Β pts: of every 100 in sales, about β1,151 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· uniQure N.V. lost $199M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$178M in fiscal 2025, β1,108.2% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $22.1M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$22.1M
12 insiders
Of sales under plans
90%
$19.8M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | Matthew C KapustaCEO, Managing Director, Director | Sold plan | 21,082 | $45.16 | $1.0M | Form 4 |
| Jun 30, 2026 | Walid Abi-SaabChief Medical Officer | Sold plan | 30,000 | $46.42 | $1.4M | Form 4 |
| Jun 30, 2026 | Jack KayeDirector | Sold plan | 21,167 | $46.44 | $1.0M | Form 4 |
| Jun 26, 2026 | Walid Abi-SaabChief Medical Officer | Sold | 1,434 | $46.86 | $0.1M | Form 4 |
| Jun 25, 2026 | Matthew C KapustaCEO, Managing Director, Director | Sold plan | 28,716 | $50.02 | $1.4M | Form 4 |
| Jun 24, 2026 | Matthew C KapustaCEO, Managing Director, Director | Sold plan | 6,696 | $50.00 | $0.3M | Form 4 |
| Jun 18, 2026 | Matthew C KapustaCEO, Managing Director, Director | Sold plan | 41,671 | $50.00 | $2.1M | Form 4 |
| Jun 17, 2026 | Madhavan BalachandranDirector | Sold plan | 11,685 | $45.06 | $0.5M | Form 4 |
| Jun 17, 2026 | Matthew C KapustaCEO, Managing Director, Director | Sold plan | 164,429 | $44.32 | $7.3M | Form 4 |
| Jun 17, 2026 | Jack KayeDirector | Sold plan | 5,295 | $42.57 | $0.2M | Form 4 |
| Jun 15, 2026 | Jeannette PottsChief Legal Officer | Sold | 5,237 | $27.67 | $0.1M | Form 4 |
| Jun 15, 2026 | Madhavan BalachandranDirector | Sold plan | 10,000 | $27.85 | $0.3M | Form 4 |
| Jun 11, 2026 | Rachelle Suzanne JacquesDirector | Sold | 1,993 | $27.06 | $0.1M | Form 4 |
| Jun 11, 2026 | Jeremy P. SpringhornDirector | Sold | 1,993 | $27.06 | $0.1M | Form 4 |
| Jun 11, 2026 | Kylie O'KeefeChief Customer & Strat Officer | Sold | 15,936 | $27.06 | $0.4M | Form 4 |
| Jun 11, 2026 | Leonard E PostDirector | Sold | 1,993 | $27.06 | $0.1M | Form 4 |
| Jun 11, 2026 | Madhavan BalachandranDirector | Sold | 1,993 | $27.06 | $0.1M | Form 4 |
| Jun 11, 2026 | David D. MeekDirector | Sold | 1,993 | $27.06 | $0.1M | Form 4 |
| Jun 11, 2026 | Robert GutDirector | Sold plan | 2,726 | $27.06 | $0.1M | Form 4 |
| Jun 11, 2026 | Jack KayeDirector | Sold | 1,993 | $27.06 | $0.1M | Form 4 |
| Jun 10, 2026 | Robert GutDirector | Sold plan | 7,552 | $26.05 | $0.2M | Form 4 |
| Jun 3, 2026 | Jack KayeDirector | Sold plan | 2,645 | $30.01 | $0.1M | Form 4 |
| May 8, 2026 | Walid Abi-SaabChief Medical Officer | Sold plan | 45,000 | $25.06 | $1.1M | Form 4 |
| Mar 4, 2026 | Matthew C KapustaCEO, Managing Director, Director | Sold | 14,581 | $9.06 | $0.1M | Form 4 |
| Mar 4, 2026 | Walid Abi-SaabChief Medical Officer | Sold | 808 | $9.06 | $0.0M | Form 4 |
| Mar 4, 2026 | Christian KlemtChief Financial Officer | Sold | 12,000 | $9.06 | $0.1M | Form 4 |
| Mar 4, 2026 | Jeannette PottsChief Legal Officer | Sold | 3,412 | $9.06 | $0.0M | Form 4 |
| Mar 2, 2026 | Walid Abi-SaabChief Medical Officer | Sold | 1,660 | $9.95 | $0.0M | Form 4 |
| Mar 2, 2026 | Christian KlemtChief Financial Officer | Sold | 12,532 | $9.95 | $0.1M | Form 4 |
| Mar 2, 2026 | Matthew C KapustaCEO, Managing Director, Director | Sold | 34,437 | $9.95 | $0.3M | Form 4 |
| Mar 2, 2026 | Jeannette PottsChief Legal Officer | Sold | 8,578 | $9.95 | $0.1M | Form 4 |
| Feb 25, 2026 | Matthew C KapustaCEO, Managing Director, Director | Sold | 12,378 | $23.86 | $0.3M | Form 4 |
| Feb 25, 2026 | Christian KlemtChief Financial Officer | Sold | 6,217 | $23.86 | $0.1M | Form 4 |
| Jan 12, 2026 | Robert GutDirector | Sold plan | 25,613 | $24.62 | $0.6M | Form 4 |
| Jan 9, 2026 | Jack KayeDirector | Sold plan | 6,390 | $27.28 | $0.2M | Form 4 |
| Nov 6, 2025 | Robert GutDirector | Sold plan | 31,434 | $27.26 | $0.9M | Form 4 |
| Nov 4, 2025 | Jack KayeDirector | Sold plan | 38,810 | $30.34 | $1.2M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· uniQure N.V. has $8.3M more cash than debt.
Cash, debt and the ratios that show how comfortably uniQure N.V. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $556M | $228M | $241M | $159M | $80.2M |
| Debt incl. finance leases | $136M | $144M | $148M | $66.0M | $71.9M |
| Net debt / EBITDA | β1.3x | β | β | β | β |
| Debt / equity | 0.2x | 0.3x | 0.7x | β | 0.4x |
| Interest coverage | 41.6x | β12.2x | β6.8x | β2.9x | β3.0x |
| Current ratio | 17.1x | 6.3x | 8.8x | 9.7x | 10.4x |
| Quick ratio | 17.1x | 6.2x | 8.7x | 9.7x | 10.4x |
| Total assets | $809M | $705M | $832M | $557M | $825M |
| Total liabilities | $213M | $229M | $624M | $563M | $626M |
| Shareholders' equity | $596M | $476M | $208M | β$6.8M | $199M |
| Net debt (β = net cash) | β$421M | β$83.5M | β$93.8M | β$92.9M | β$8.3M |
KIRA Β· Its return on capital was β76.8%: every 100 invested in the business earned about β77 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· uniQure N.V. passes 4 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 9 | 3 / 9 | 4 / 9 | 2 / 9 | 6 / 9 | 2 / 9 | 4 / 9 | 4 / 9 | 4 / 9 |
| Accruals ratio | β0.6% | β7.5% | β3.0% | β7.1% | 2.5% | 7.2% | 2.4% | β21.2% | β8.2% | β3.0% |
| Altman Z'' | β4.62 | β4.41 | β1.35 | 1.25 | β2.87 | 8.47 | 1.86 | β0.87 | β4.73 | β1.71 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $25.1M | $13.1M | $11.3M | $7.3M | $37.5M | $524M | $106M | $15.8M | $27.1M | $16.1M |
| Gross profit | $23.8M | $12.3M | $10.1M | $5.6M | $34.6M | $499M | $105M | $15.8M | $25.9M | $14.4M |
| Research and development | $72.5M | $72.2M | $74.8M | $94.7M | $122M | $144M | $198M | $215M | $144M | $141M |
| Operating income | β$71.9M | β$71.3M | β$88.2M | β$121M | β$125M | $311M | β$143M | β$283M | β$184M | β$185M |
| Interest expense | $2.2M | $2.2M | $2.2M | $3.8M | $3.8M | $7.5M | $11.7M | $41.6M | $63.7M | $62.0M |
| Pretax income | β$72.2M | β$79.5M | β$83.1M | β$124M | β$141M | $333M | β$128M | β$307M | β$237M | β$193M |
| Income tax | $1.1M | β$0.2M | $0.2M | β | β$16.4M | $3.2M | β$1.5M | $1.9M | $2.4M | $5.6M |
| Net income | β$73.4M | β$79.3M | β$83.3M | β$124M | β$125M | $330M | β$127M | β$308M | β$240M | β$199M |
| Net income to common | β$73.4M | β$79.3M | β$83.3M | β$124M | β$125M | $330M | β$127M | β$308M | β$240M | β$199M |
| Diluted EPS | β$2.93 | β$2,940.00 | β$2,340.00 | β$3.11 | β$2.81 | $7.04 | β$2.71 | β$6.47 | β$4.92 | β$3.46 |
| Diluted shares | 0.03B | 0.03B | 0.04B | 0.04B | 0.04B | 0.05B | 0.05B | 0.05B | 0.05B | 0.06B |
| Cash flow | ||||||||||
| Cash from operations | β$72.2M | β$64.3M | β$76.0M | β$98.7M | β$135M | $288M | β$145M | β$146M | β$183M | β$178M |
| Capital expenditure | $15.3M | $4.5M | $2.4M | $5.7M | $7.3M | $17.4M | $17.7M | $7.2M | $3.4M | $0.4M |
| Free cash flow | β$87.5M | β$68.7M | β$78.4M | β$104M | β$142M | $271M | β$163M | β$153M | β$186M | β$178M |
| Depreciation and amortization | $5.5M | $7.5M | $12.4M | $6.7M | $10.6M | $7.3M | $8.5M | $11.9M | $12.6M | $14.8M |
| Stock-based compensation | $6.2M | $10.3M | $10.7M | $17.5M | $21.8M | $25.6M | $34.2M | $35.1M | $22.3M | $17.7M |
| Acquisitions | β | β | β | β | β | $49.9M | $1.9M | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $132M | $159M | $235M | $378M | $245M | $556M | $228M | $241M | $159M | $80.2M |
| Total debt | $20.2M | $24.0M | $48.2M | $46.5M | $42.4M | $136M | $144M | $148M | $66.0M | $71.9M |
| Current assets | $144M | $163M | $237M | $384M | $259M | $628M | $477M | $652M | $390M | $656M |
| Current liabilities | $22.7M | $19.2M | $20.0M | $31.6M | $27.3M | $36.8M | $75.9M | $73.7M | $40.1M | $62.9M |
| Inventory | β | β | β | β | β | β | $6.9M | $12.0M | β | β |
| Property and equipment, net | $35.7M | $34.3M | $29.2M | $28.8M | $32.3M | $43.5M | $50.5M | $46.5M | $20.4M | $13.8M |
| Goodwill | $0.5M | $0.5M | $0.5M | $0.5M | $0.5M | $27.6M | $25.6M | $26.4M | $22.4M | $25.4M |
| Intangible assets | $8.3M | $9.6M | $5.2M | $5.4M | $3.4M | $62.7M | $58.8M | $60.5M | $71.0M | $72.8M |
| Total assets | $190M | $210M | $274M | $449M | $340M | $809M | $705M | $832M | $557M | $825M |
| Total liabilities | $127M | $120M | $94.3M | $126M | $96.5M | $213M | $229M | $624M | $563M | $626M |
| Shareholders' equity | $63.6M | $89.4M | $180M | $323M | $244M | $596M | $476M | $208M | β$6.8M | $199M |
| Margins | ||||||||||
| Gross margin | 94.6% | 93.8% | 89.3% | 77.3% | 92.3% | 95.2% | 98.8% | 99.6% | 95.3% | 89.5% |
| Operating margin | β286.7% | β544.3% | β781.9% | β1,663.8% | β334.3% | 59.3% | β134.4% | β1,785.5% | β679.6% | β1,151.4% |
| EBITDA margin | β264.7% | β486.8% | β671.9% | β1,572.2% | β306.0% | 60.7% | β126.4% | β1,710.4% | β633.0% | β1,059.7% |
| Net margin | β292.4% | β604.7% | β738.2% | β1,705.8% | β333.3% | 62.9% | β119.1% | β1,947.1% | β883.4% | β1,236.0% |
| FCF margin | β348.5% | β524.4% | β695.0% | β1,433.0% | β378.8% | 51.6% | β152.8% | β966.3% | β686.2% | β1,108.2% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β239.4% | 175.7% | β28.8% | β196.2% | β | β76.8% |
| Return on capital employed | β42.9% | β37.5% | β34.7% | β29.1% | β40.1% | 40.2% | β22.8% | β37.3% | β35.7% | β24.3% |
| Return on equity | β115.3% | β103.6% | β61.9% | β49.4% | β44.1% | 78.5% | β23.7% | β90.2% | β238.5% | β207.1% |
| Return on assets | β38.6% | β39.6% | β34.5% | β34.4% | β31.7% | 57.3% | β16.7% | β40.1% | β34.5% | β28.8% |
| Return on tangible equity | β133.8% | β100.0% | β47.9% | β39.2% | β52.1% | 65.2% | β32.4% | β255.3% | β | β197.5% |
| Growth | ||||||||||
| Revenue growth | β | β47.8% | β13.9% | β35.5% | 415.2% | 1,296.8% | β79.7% | β85.1% | 71.2% | β40.6% |
| Net income growth | β | β | β | β | β | β | β138.5% | β | β | β |
| EPS growth | β | β | β | β | β | β | β138.5% | β | β | β |
| FCF growth | β | β | β | β | β | β | β160.2% | β | β | β |
| Share count change | β | 7.8% | 32.1% | 12.2% | 11.2% | 5.3% | β0.2% | 2.0% | 2.1% | 18.2% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β | β | β | β | β1.3x | β | β | β | β |
| Debt / equity | 0.3x | 0.3x | 0.3x | 0.1x | 0.2x | 0.2x | 0.3x | 0.7x | β | 0.4x |
| Interest coverage | β33.1x | β32.0x | β40.8x | β31.8x | β32.8x | 41.6x | β12.2x | β6.8x | β2.9x | β3.0x |
| Current ratio | 6.3x | 8.5x | 11.8x | 12.1x | 9.5x | 17.1x | 6.3x | 8.8x | 9.7x | 10.4x |
| Quick ratio | 6.3x | 8.5x | 11.8x | 12.1x | 9.5x | 17.1x | 6.2x | 8.7x | 9.7x | 10.4x |
| Capital allocation | ||||||||||
| Capex / revenue | 60.9% | 34.0% | 21.1% | 77.6% | 19.4% | 3.3% | 16.6% | 45.2% | 12.4% | 2.7% |
| Stock comp / revenue | 24.8% | 78.4% | 94.9% | 240.8% | 58.2% | 4.9% | 32.1% | 221.5% | 82.1% | 109.8% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 3.0 | 4.0 | 2.0 | 6.0 | 2.0 | 4.0 | 4.0 | 4.0 |
| Altman Z'' | β4.6 | β4.4 | β1.4 | 1.2 | β2.9 | 8.5 | 1.9 | β0.9 | β4.7 | β1.7 |
| Accruals ratio | β0.6% | β7.5% | β3.0% | β7.1% | 2.5% | 7.2% | 2.4% | β21.2% | β8.2% | β3.0% |
Source: SEC EDGAR XBRL filings (CIK 0001590560). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
